Press release

November 16, 2021

Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe

November 2, 2021

Immunicom Conference Highlights Innovation in Clinical Trial Design to Advance its Breakthrough Cancer Immunotherapy Platform

October 7, 2021

Immunicom Hires Former FDA Clinician and Medical Device Reviewer to Rapidly Progress Launch of Novel Cancer Immunotherapy

September 28, 2021

Immunicom’s Alternative Subtractive Cancer Therapy Recognized with Zoom’s Healthcare Innovation Award

September 21, 2021

Immunicom Introduces 2nd Product of Immunopheresis® Therapy Platform Designed to Suppress Cancer Progression and Overcome Therapeutic Resistance

Immunicom Inc.

HEADQUARTERS

San Diego, CA

RESOURCES

Terms of Use

Privacy policy

GET IN TOUCH

Contact us

Newsletter Subscription

Immunicom’s Immunopheresis® therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies. Immunicom’s LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe.